Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Lunesta In San Diego,.7093"

Looking for quality documents?
publications icon
Immobilized rProtein Solutions SDS - German
publications icon
Immobilized rProtein Solutions SDS - French
publications icon
Immobilized rProtein Solutions SDS - Dutch
publications icon
Immobilized rProtein Solutions SDS - Swedish
publications icon
Immobilized rProtein Solutions SDS - Korean
corporate icon
XCell® ATF Systems
SIMPLIFY AND INTENSIFY XCell® ATF Systems attach to a bioreactor to intensify upstream manufacturing capacity, productivity, and throughput.
publications icon
PATsmart REBEL Calibrated Range - Minimum and Maximum Concentrations
video icon
Evaluating the new CTech FlowVPX System for UF/DF-Protein Concentration (Bristol-Myers Squibb)
An evaluation of a beta version of the FlowVPX and Viper software was performed to determine it’s potential as an inline instrument for product concentration measurement during UF/DF operation, particularly high concentration UF/DF processes that are required for subcutaneous injection formulations (greater than 150 g/L). The FlowVPX has significant potential for GMP and commercial biologics manufacturing unlike the first generation FlowVPE, which was designed as a lab scale instrument. Extensive testing was done using small and pilot scale UF/DF operations with several biologic drugs molecules from the portfolio. The FlowVPX instrument demonstrated very good comparability with other A280 based protein concentration measurements for all molecules tested (six). From a technical standpoint the FlowVPX is a GMP ready instrument, and further testing for instrument robustness and software development is ongoing at present to potentially use the instrument in the GMP space within the near future. Speaker: Jay West, Ph.D., Principal Scientist Biologics Process Development – BMS.
external link icon
Repligen To Host Investor Day 2022
WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the Nasdaq MarketSite in New York City from 8:20 to 11:30 a.m. EDT. The event will feature presentations by several members of the company’s leadership team and will include Q&A discussion between the audience and Repligen panel members. A live webcast of “Repligen Investor Day 2022” will be accessible through the Investor Relations website at www.repligen.com and will be available for replay for a limited period of time following the event. In-person event registration is limited to institutional investors and analysts, while webcast registration is available to all. About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing
external link icon
Repligen Added to Russell 3000 Index
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support